22,388
Total Claims
$4.6M
Drug Cost
2,679
Beneficiaries
$1,735
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+14%
Cost per patient vs peers
$1,735 vs $1,524 avg
+58%
Brand preference vs peers
21.5% vs 13.7% avg
Brand vs Generic
79% generic
Brand: 4,814 claims · $4.2M
Generic: 17,574 claims · $406K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 1,176 | $1.1M |
| Rivaroxaban | 727 | $715K |
| Sacubitril/Valsartan | 583 | $632K |
| Evolocumab | 474 | $345K |
| Dapagliflozin Propanediol | 264 | $240K |
| Empagliflozin | 197 | $193K |
| Semaglutide | 154 | $169K |
| Tirzepatide | 126 | $152K |
| Dronedarone Hcl | 89 | $133K |
| Ticagrelor | 169 | $130K |
| Semaglutide | 52 | $56K |
| Bempedoic Acid/Ezetimibe | 90 | $46K |
| Alirocumab | 43 | $43K |
| Bempedoic Acid | 71 | $41K |
| Ezetimibe | 806 | $35K |
Prescribing Profile
Patient Profile
74
Avg Age
54%
Female
1.86
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data